Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | SQLE | Q14534 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699303 | 1.00 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3642766 | 0.81 | KMT2A (0.50) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL4451128 | 0.79 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3019152 | 0.79 | KDM4E (0.45) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL5188887 | 0.79 | KDM4E (0.45) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL4451127 | 0.79 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3019155 | 0.79 | KDM4E (0.45) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3663788 | 0.79 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3663786 | 0.79 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3957765 | 0.79 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105685-B2 | Viricides treating Human Immunodeficiency Viruses; antitumor agents | TRAVIS CRAIG R | 2006-09-12 | — | — | US | claimed |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | IMMUGEN PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-20030171372-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. (US) | 2003-09-11 | — | — | US | claimed |
| US-20030158191-A1 | Cannabinol derivatives | TRAVIS CRAIG R (US) | 2003-08-21 | — | — | US | claimed |
| US-6541510-B2 | Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. | IMMUGEN PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| JP-2002539246-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-20020068738-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002026728-A2 | ANTIVIRAL METHODS AND COMPOUNDS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | claimed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-8586767-B2 | Method for treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG RICK (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020037923-A1 | Resorcinolic compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171372-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | KMT2A 3188/4885ALOX15 403/4885MAPT 3386/4885 |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | KMT2A 1790/4885ALOX15 480/4885MAPT 2487/4885 |
| US-20030158191-A1 | Cannabinol derivatives | CNR2, CNR1, GPR18 | KMT2A 3154/4885ALOX15 906/4885MAPT 594/4885 |
| US-20020037923-A1 | Resorcinolic compounds | VHL, HRAS, CYP46A1 | KMT2A 3616/4885ALOX15 2533/4885MAPT 4261/4885 |
| US-20020068738-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | KMT2A 3188/4885ALOX15 403/4885MAPT 3386/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | KMT2A 1790/4885ALOX15 480/4885MAPT 2487/4885 |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | CNR1, CNR2, MKI67 | KMT2A 2456/4885ALOX15 118/4885MAPT 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.